Ready 8-Ks
5
Latest filing
August 13, 2026, 4:04 PM ET
Top materiality
0.90
Event mix
earnings ×2 · leadership ×1 · other_material ×1
Sentiment
2 pos · 0 neg · 3 neu
Latest earnings
reported 2026-Q1
Recent 8-K filings for AKTS
Highest-materiality recent filing
Aktis Oncology Q1 2026 net loss $18.3M; cash $538.5M; Phase 1b trials advancing
- Net loss $18.3M vs $15.0M YoY; R&D expense $20.0M (+$4.1M) driven by clinical trial costs.
- Cash, equivalents & marketable securities $538.5M (up from $226.8M Dec 2025); runway into 2029.
-
Aktis Oncology Q2 net loss $24.1M; cash $517.3M funds operations into 2029
Net loss $24.1M for Q2 2026 vs $18.1M prior-year; interest income net of $4.8M.
-
Aktis Oncology Q1 2026 net loss $18.3M; cash $538.5M; Phase 1b trials advancing
Net loss $18.3M vs $15.0M YoY; R&D expense $20.0M (+$4.1M) driven by clinical trial costs.
-
Aktis Oncology: FDA clears IND for AKY-2519; full-year 2025 net loss widens to $63.7M
FDA cleared IND for AKY-2519 (B7-H3 miniprotein radioconjugate); Phase 1b trial for solid tumors expected mid-2026.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event earnings